Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | KCNJ1 | P48048 | 8/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655760 | 0.91 | KCNJ1 (0.54) | CYP19A1KMT2AKCNJ1KCNH2HRH3 | |
| SCHEMBL994055 | 0.84 | CYP19A1 (0.57) | CYP19A1KMT2APOLBPKM | |
| SCHEMBL6647694 | 0.78 | MAPT (0.50) | CYP19A1KMT2APOLBPKM | |
| SCHEMBL5656114 | 0.78 | SMN1; SMN2 (0.63) | KMT2ATSHRPKM | |
| SCHEMBL5655128 | 0.78 | POLB (0.63) | CYP19A1KMT2APOLBPKM | |
| Nitric Acid SCHEMBL6033169 | 0.76 | PLAU (0.41) | PKM | |
| SCHEMBL4829103 | 0.76 | CYP19A1 (0.57) | CYP19A1KMT2AKCNJ1KCNH2HRH3 | |
| SCHEMBL10786317 | 0.76 | CYP19A1 (0.51) | CYP19A1 | |
| SCHEMBL7138301 | 0.75 | CYP19A1 (0.67) | CYP19A1KMT2ATSHR | |
| Hydrochloric Acid SCHEMBL29006841 | 0.74 | CYP19A1 (0.50) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1187816-B1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | CELLTECH R&D LTD (GB) | 2006-12-20 | — | — | EP | disclosed |
| US-20040180914-A1 | 5-Cyano-2-aminopyrimidine derivatives | CELLTECH R&D LIMTIED | 2004-09-16 | — | — | US | disclosed |
| US-6579983-B1 | Potent and selective inhibitors of receptor tyrosine kinases involved in angiogenesis, especially KDR kinase and/or FGFr kinase | CELLTECH R&D LIMITED (GB) | 2003-06-17 | — | — | US | disclosed |
| US-20020147339-A1 | 5-cyano-2-aminopyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2002-10-10 | — | — | US | disclosed |
| EP-1187816-A1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | Celltech R&D Limited (GB) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000078731-A1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | CELLTECH R&D LIMITED (GB) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180914-A1 | 5-Cyano-2-aminopyrimidine derivatives | FLT1, FGFR1, KDR | CYP19A1 350/4885KMT2A 2638/4885KCNJ1 3062/4885 |
| US-20020147339-A1 | 5-cyano-2-aminopyrimidine derivatives | FLT1, FGFR1, KDR | CYP19A1 371/4885KMT2A 2620/4885KCNJ1 3234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.